News

Filter

Current filters:

GenentechXolair

1 to 9 of 71 results

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Novartis presents strong new Ph III results with omalizumab in CSU

Novartis presents strong new Ph III results with omalizumab in CSU

05-10-2013

Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective…

DermatologicalsGenentechNovartisOmalizumabPharmaceuticalResearchXolair

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

PDL BioPharma sues Roche’s Genentech over royalties

02-09-2010

US drug developer PDL BioPharma (Nasdaq: PDL) said yesterday that it has filed suit in a Nevada state…

AvastinBiotechnologyFinancialGenentechHerceptinLegalLucentisPDL BioPharmaPharmaceuticalRocheXolair

1 to 9 of 71 results

COMPANY SPOTLIGHT

Menarini

Back to top